Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Analyst Ratings

Analyst Ratings

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Downgrades
  • Price Target

Why This 10X Genomics Analyst Is Turning Bearish, Slashing Price Target

By Priya Nigam
July 15, 11:29 AM
10X Genomics Inc (NASDAQ: TXG) reported preliminary second-quarter revenues Thursday that were meaningfully below the consensus estimates.

TXG

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Equal-Weight on Lennox International, Lowers Price Target to $222

By Benzinga Newsdesk
July 15, 11:25 AM
Morgan Stanley analyst Joshua Pokrzywinski maintains Lennox International (NYSE:LII) with a Equal-Weight and lowers the price target from $238 to $222.

LII

Read More
3 minute read
  • Analyst Ratings
  • Earnings
  • News

Will Strong Demand Drive Steel Dynamics’ (STLD) Q2 Earnings?

By Zacks
July 15, 11:24 AM
Steel Dynamics, Inc. STLD is set to release second-quarter 2022 results after the closing bell on Jul 20.

CE

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $63

By Benzinga Newsdesk
July 15, 11:22 AM
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $55 to $63.

LEGN

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Equal-Weight on Latham Group, Lowers Price Target to $8

By Benzinga Newsdesk
July 15, 11:19 AM
Morgan Stanley analyst Joshua Pokrzywinski maintains Latham Group (NASDAQ:SWIM) with a Equal-Weight and lowers the price target from $12 to $8.

SWIM

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Equal-Weight on Kimco Realty, Lowers Price Target to $22

By Benzinga Newsdesk
July 15, 11:16 AM
Morgan Stanley analyst Richard Hill maintains Kimco Realty (NYSE:KIM) with a Equal-Weight and lowers the price target from $25 to $22.

KIM

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Overweight on Invitation Homes, Lowers Price Target to $40.5

By Benzinga Newsdesk
July 15, 11:14 AM
Morgan Stanley analyst Richard Hill maintains Invitation Homes (NYSE:INVH) with a Overweight and lowers the price target from $42.5 to $40.5.

INVH

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Equal-Weight on Intuitive Surgical, Lowers Price Target to $225

By Benzinga Newsdesk
July 15, 11:11 AM
Morgan Stanley analyst Cecilia Furlong maintains Intuitive Surgical (NASDAQ:ISRG) with a Equal-Weight and lowers the price target from $300 to $225.

ISRG

Read More
1 minute read
  • Analyst Ratings

What 10 Analyst Ratings Have To Say About DexCom

By Benzinga Insights
July 15, 11:07 AM
DexCom (NASDAQ:DXCM) has observed the following analyst ratings within the last quarter:

DXCM

Read More
1 minute read
  • Analyst Ratings

Expert Ratings for Alnylam Pharmaceuticals

By Benzinga Insights
July 15, 11:03 AM
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:

ALNY

Posts pagination

Previous 1 … 4,274 4,275 4,276 … 4,420 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service